Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis
Objectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab tr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2021-07-01
|
| Series: | Endocrine Regulations |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/enr-2021-0018 |